XML 43 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company has one reportable segment relating to the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. The Company’s Chief Operating Decision Maker
(“CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the condensed consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and the change in fair value of warrants are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the condensed consolidated statements of cash flows. Other segment items include interest income, interest expense, and change in the fair value of warrants. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the CODM and are reported on the condensed consolidated statements of cash flows. The following table presents certain financial data for the Company’s reportable segment (in thousands):
Three months ended,
20252024
Clinical trial expenses$4,192 $2,302 
Employee related research and development expenses2,298 2,243 
Chemistry, manufacturing and controls expenses646 1,194 
Other research and development expenses1,136 1,887 
Contract and grant reimbursements(489)(67)
Employee related general and administrative expenses1,087 919 
Professional fees and other general and administrative expenses1,866 1,762 
Other segment items473 1,587 
Segment net loss$11,209 $11,827 

March 31,
2025		December 31,
2024
Total segment assets$28,144 $28,178